Browse > Article
http://dx.doi.org/10.7586/jkbns.2017.19.2.107

Comparison of Lipid Profile Ratios in Patients with High-grade Brain Cancers according to the Presence of Recurrence during Cancer-related Therapy  

Kim, Sanghee (College of Nursing.Research Institute of Nursing Science, Keimyung University)
Publication Information
Journal of Korean Biological Nursing Science / v.19, no.2, 2017 , pp. 107-112 More about this Journal
Abstract
Purpose: The purpose of this study was to identify the lipid profile ratios as factors affecting disease progress in patients with high-grade primary brain cancers undergoing concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy. Methods: The levels of lipid profile ratios were evaluated by looking at the total cholesterol (TC) to high-density lipoprotein (HDL)-cholesterol (TC/HDL-c), low-density lipoprotein (LDL)-cholesterol to HDL-cholesterol (LDL-c/HDL-c), and triglycerides to HDL-cholesterol (TG/HDL-c). This descriptive research was conducted 7 months after the initiation of CCRT and adjuvant chemotherapy. Results: A total of 36 patients with newly diagnosed primary malignant brain cancer were included in the study. The levels of lipid profile ratios such as TC/HDL-c, LDL-c/HDL-c, TG/HDL-c were significantly different between the patients with and without disease progress at 7 months after initiation of CCRT and adjuvant chemotherapy. Conclusion: The lipid profile ratios were indicators affecting disease prognosis with tumor-related factors at 7 months after initiation of CCRT and adjuvant chemotherapy. Therefore, lipid profile ratios indicating hyperlipidemia in patients with high-grade brain cancers should be carefully monitored during and after cancer-related therapy.
Keywords
High-grade Brain Cancers; Cancer-related Therapy; Lipid Profile Ratios;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes & Control. 2015;26(2):257-268. https://doi.org/10.1007/s10552-014-0507-y   DOI
2 Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009; 135(12): 1209-1217. https://doi.org/10.1001/archoto.2009.174   DOI
3 Li J, Wu MF, Lu HW, Zhang BZ, Wang LJ, Lin ZQ. Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer. PLoS One. 2016;11(11):1-15. http://dx.doi.org/10.1371/journal.pone.0166612   DOI
4 Huang C, Freter C. Lipid Metabolism, Apoptosis and Cancer Therapy. International Journal of Molecular Sciences. 2015;16(1):924-949. https://doi.org/10.3390/ijms16010924.   DOI
5 Wang Y, Wang ZQ, Wang FH, Lei XF, Yan SM, Wang DS et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget.2016;7(35):57290-57300. https://doi.org/10.18632/oncotarget.10145   DOI
6 Dai D, Chen B, Wang B, Tang H, Li X, Zhao Z et al. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. Journal of Cancer.2016;7(12):1747-1754. https://doi.org/ 10.7150/jca.15776   DOI
7 The Korean Brain Tumor Society. Brain Cancers Epidemiology Page[Internet]. [cited 2015 March 13]. Available from: http://www.braintumor.or.kr/public/infor/sub2_1.php.
8 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016; 131(6): 803-820. http://dx.doi.org/10.1007/s00401-016-1545-1   DOI
9 National Cancer Information Center. The Types of Brain Cancers Page [Internet]. [cited 2016 May 2]. Available from:http://www.cancer.go.kr/mbs/cancer/jsp/cancer/cancer.jsp?cancerSeq=4301&menuSeq=4302&viewType=all&id=cancer_020118000000.
10 Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH et al. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer Research and Treatment. 2017;49(1):193-203. http://dx.doi.org/10.4143/crt.2015.473   DOI
11 Roy S, Lahiri D, Maji T, Biswas J. Recurrent Glioblastoma: Where we stand. South Asian Journal of Cancer. 2015;4(4):163-173. http://dx.doi.org/10.4103/2278-330X.175953   DOI
12 Sarica FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H et al. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian Journal of Neurosurgery. 2012; 7(4): 181-190. http://dx.doi.org/10.4103/1793-5482.106650   DOI
13 Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R et al. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. Journal of Neurosciences in Rural Practice. 2013;4(5):46-55. http://dx.doi.org/10.4103/0976-3147.116455   DOI
14 Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. Journal of Neurosurgery. 2011;115(2):220-229. http://dx.doi.org/10.3171/2011.3.JNS10495   DOI
15 Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management. 2009; 5:757-765. https://doi.org/10.2147/VHRM.S6269   DOI
16 Upadhyay RK. Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders. Journal of Lipids. 2015;8:971453. https://doi.org/10.1155/2015/971453   DOI
17 Bielecka-Dabrowa A, Hannam S, Rysz J, Banach M. Malignancy-associated dyslipidemia. Open Cardiovascular Medicine Journal.2011;5:35-40. https://do i.org/10.2174/1874192401105010035   DOI
18 Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapies.2004;3(4):294-300. https://doi.org/10.1177/1534735404270335   DOI
19 Nelson RH. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Prim Care. 2013;40(1):195-211. https://doi.org/10.1016/j.pop.2012.11.003   DOI
20 Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G, Mehdizadeh J. The Valuable Role of Measuring Serum Lipid Profile in Cancer Progression. Oman Med J. 2015;3(5):353-357. https://doi.org/10.5001/omj.2015.71   DOI
21 Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349-2356. https://doi.org/10.1158/1055-9965.EPI-14-0458   DOI
22 Gupta RK, Patel AK, Kumari R, Chugh S, Shrivastav C, Mehra S et al. Interactions between oxidative stress, lipid profile and antioxidants in breast cancer: a case control study. Asian Pacific Journal of Cancer Prevention. 2012;13(12): 6295-6298. https://doi.org/10.7314/APJCP.2012.13.12.6295   DOI
23 McGrowder D, Riley C, Morrison EY, Gordon L. The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer. Cholesterol. 2011:1-9. https://doi.org/10.1155/2011/496925   DOI
24 Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after recurrence: A changing paradigm. Journal of the Egyptian National Cancer Institute. 2016;28(4):199-210. http://dx.doi.org/10.1016/j.jnci.2016.07.001   DOI